Ario Pharma Ltd is developing new therapeutics for the treatment of pain.
A TRPA1 lead optimisation project is underway, focusing on chronic pain: The company is actively working to identify potent, safe, orally bioavailable small molecule TRPA1 antagonists to treat neuropathic and inflammatory pain.
The Company developed a best-in-class oral TRPV1 inhibitor that was acquired by PILA Pharma in 2016 and will be evaluated in patients with Type-2 diabetes.
Please contact us to arrange a meeting at one of the events we are attending.
Ario Pharma Acquires PharmEste’s TRPA1 Research Assets